Get informed when a big investor buys or sells
+ FollowOvervalued by 72.2% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $119.98 Million |
|---|---|
| Enterprise Value | $137.80 Million |
| Earnings per Share | $-0.07 |
| Beta | 1.68 |
| Outstanding Shares | 31,430,748 |
| P/E Ratio | -94.66 |
|---|---|
| PEG | 26.76 |
| Price to Sales | 1.27 |
| Price to Book Ratio | 3.8 |
| Enterprise Value to Revenue | 1.29 |
| Enterprise Value to EBIT | 32.16 |
| Enterprise Value to Net Income | -109 |
| Total Debt to Enterprise | 0.19 |
| Debt to Equity | 0.54 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. I...